Global Blood Therapeutics (NASDAQ:GBT) reported Q1 EPS of ($1.26), $0.04 better than the analyst estimate of ($1.30). Revenue for the quarter came in at $55.16 million versus the consensus estimate of $56.14 million.
Global Blood Therapeutics (NASDAQ:GBT) reported Q1 EPS of ($1.26), $0.04 better than the analyst estimate of ($1.30). Revenue for the quarter came in at $55.16 million versus the consensus estimate of $56.14 million.